• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.

作者信息

Lapp Sean L, Bewtra Meenakshi, Lewis James D

机构信息

Messiah University, New Holland, Pennsylvania.

Division of Gastroenterology and Hepatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

Clin Gastroenterol Hepatol. 2024 Feb;22(2):420-422.e2. doi: 10.1016/j.cgh.2023.06.003. Epub 2023 Jun 17.

DOI:10.1016/j.cgh.2023.06.003
PMID:37331412
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10725512/
Abstract
摘要

相似文献

1
Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.炎症性肠病患者结核暴露的系列检测结果：单次检测不够。
Clin Gastroenterol Hepatol. 2024 Feb;22(2):420-422.e2. doi: 10.1016/j.cgh.2023.06.003. Epub 2023 Jun 17.
2
Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease.肿瘤坏死因子α抑制剂：炎症性肠病中结核感染的筛查
Med J Aust. 2008 Feb 4;188(3):168-70. doi: 10.5694/j.1326-5377.2008.tb01565.x.
3
[Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis].[关于结核病以及英夫利昔单抗治疗炎症性肠病的共识指南。西班牙克罗恩病和溃疡性结肠炎工作组]
Gastroenterol Hepatol. 2003 Jan;26(1):29-33. doi: 10.1016/s0210-5705(03)70338-0.
4
[Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update].[关于结核病及英夫利昔单抗治疗炎症性肠病的建议。2006年更新版]
Gastroenterol Hepatol. 2006 Feb;29(2):81-4. doi: 10.1157/13083915.
5
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.炎症性肠病患者中无反应性的高发生率限制了英夫利昔单抗治疗前结核菌素纯蛋白衍生物筛查的实用性。
Clin Gastroenterol Hepatol. 2004 Apr;2(4):309-13. doi: 10.1016/s1542-3565(04)00060-6.
6
Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab.英夫利昔单抗治疗后 2 例炎症性肠病患儿发生播散性结核。
Pediatr Infect Dis J. 2014 Jul;33(7):779-81. doi: 10.1097/INF.0000000000000286.
7
New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.3例接受白细胞介素-17A抑制剂司库奇尤单抗治疗的患者新发炎症性肠病：病例系列
Am J Gastroenterol. 2019 Jan;114(1):179-180. doi: 10.1038/s41395-018-0422-z.
8
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.重新调整英夫利昔单抗治疗方案：皮下注射英夫利昔单抗为患者提供了更便捷和更有益的治疗选择。
Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3.
9
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.尽管进行了潜伏感染筛查，抗 TNF 治疗仍存在发生结核的风险。
J Crohns Colitis. 2013 Apr;7(3):208-12. doi: 10.1016/j.crohns.2012.05.012. Epub 2012 Jun 5.
10
Aggressive plasmablastic multiple myeloma in a 42-year-old: is inflammatory bowel disease or infliximab treatment to be blamed?一名42岁患者的侵袭性浆母细胞性多发性骨髓瘤：是炎性肠病还是英夫利昔单抗治疗所致？
BMJ Case Rep. 2013 Oct 29;2013:bcr2013200607. doi: 10.1136/bcr-2013-200607.

本文引用的文献

1
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).一项前瞻性成人炎症性肠病研究队列（SPARC IBD）的研究进展和初步发现。
Inflamm Bowel Dis. 2022 Feb 1;28(2):192-199. doi: 10.1093/ibd/izab071.
2
Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors.接受非肿瘤坏死因子抑制剂治疗的炎症性肠病患者中干扰素-γ释放试验结果的阳转频率
Front Med (Lausanne). 2021 May 21;8:670242. doi: 10.3389/fmed.2021.670242. eCollection 2021.
3
Tuberculosis - United States, 2020.结核病-美国，2020 年。
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):409-414. doi: 10.15585/mmwr.mm7012a1.
4
Prevalence of Inflammatory Bowel Disease in Pediatric and Adult Populations: Recent Estimates From Large National Databases in the United States, 2007-2016.美国2007 - 2016年大型国家数据库中儿童和成人炎症性肠病的患病率：近期估计
Inflamm Bowel Dis. 2020 Mar 4;26(4):619-625. doi: 10.1093/ibd/izz182.
5
Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.不确定的 QuantiFERON-TB Gold 增加炎症性肠病治疗延迟和住院的可能性。
Inflamm Bowel Dis. 2017 Dec 19;24(1):217-226. doi: 10.1093/ibd/izx019.
6
Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.873例接受肿瘤坏死因子-α抑制剂治疗的炎症性肠病患者发生机会性结核感染的风险
Scand J Gastroenterol. 2015 Mar;50(3):312-20. doi: 10.3109/00365521.2014.1000960. Epub 2015 Jan 12.
7
Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.皮质类固醇和免疫抑制疗法会影响炎症性肠病患者的 QuantiFERON TB Gold 检测结果。
J Crohns Colitis. 2012 May;6(4):419-24. doi: 10.1016/j.crohns.2011.09.011. Epub 2011 Oct 19.
8
Risk for active tuberculosis in inflammatory bowel disease patients.
Clin Gastroenterol Hepatol. 2007 Sep;5(9):1070-5. doi: 10.1016/j.cgh.2007.04.007. Epub 2007 Jul 12.